Literature DB >> 24492303

Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency.

Louise Saul1, Debra H Josephs1, Keith Cutler2, Andrew Bradwell2, Panagiotis Karagiannis3, Chris Selkirk4, Hannah J Gould5, Paul Jones6, James F Spicer7, Sophia N Karagiannis3.   

Abstract

BACKGROUND: Due to genetic similarities with humans, primates of the macaque genus such as the cynomolgus monkey are often chosen as models for toxicology studies of antibody therapies. IgE therapeutics in development depend upon engagement with the FcεRI and FcεRII receptors on immune effector cells for their function. Only limited knowledge of the primate IgE immune system is available to inform the choice of models for mechanistic and safety evaluations.
METHODS: The recognition of human IgE by peripheral blood lymphocytes from cynomolgus monkey and man was compared. We used effector cells from each species in ex vivo affinity, dose-response, antibody-receptor dissociation and potency assays.
RESULTS: We report cross-reactivity of human IgE Fc with cynomolgus monkey cells, and comparable binding kinetics to peripheral blood lymphocytes from both species. In competition and dissociation assays, however, human IgE dissociated faster from cynomolgus monkey compared with human effector cells. Differences in association and dissociation kinetics were reflected in effector cell potency assays of IgE-mediated target cell killing, with higher concentrations of human IgE needed to elicit effector response in the cynomolgus monkey system. Additionally, human IgE binding on immune effector cells yielded significantly different cytokine release profiles in each species.
CONCLUSION: These data suggest that human IgE binds with different characteristics to human and cynomolgus monkey IgE effector cells. This is likely to affect the potency of IgE effector functions in these two species, and so has relevance for the selection of biologically-relevant model systems when designing pre-clinical toxicology and functional studies.

Entities:  

Keywords:  IgE; IgE Fc receptors; allergooncology; allergy; antibody effector functions; cancer; cross-species reactivity; cynomolgus monkey; non-human primate

Mesh:

Substances:

Year:  2014        PMID: 24492303      PMCID: PMC3984339          DOI: 10.4161/mabs.27828

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  47 in total

1.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.

Authors:  Konstantin Arnold; Lorenza Bordoli; Jürgen Kopp; Torsten Schwede
Journal:  Bioinformatics       Date:  2005-11-13       Impact factor: 6.937

2.  Clustal W and Clustal X version 2.0.

Authors:  M A Larkin; G Blackshields; N P Brown; R Chenna; P A McGettigan; H McWilliam; F Valentin; I M Wallace; A Wilm; R Lopez; J D Thompson; T J Gibson; D G Higgins
Journal:  Bioinformatics       Date:  2007-09-10       Impact factor: 6.937

3.  Binding of cynomolgus monkey IgE to a humanized anti-human IgE antibody and human high affinity IgE receptor.

Authors:  Y G Meng; N Singh; W L Wong
Journal:  Mol Immunol       Date:  1996 May-Jun       Impact factor: 4.407

4.  Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma.

Authors:  H J Gould; G A Mackay; S N Karagiannis; C M O'Toole; P J Marsh; B E Daniel; L R Coney; V R Zurawski; M Joseph; M Capron; M Gilbert; G F Murphy; R Korngold
Journal:  Eur J Immunol       Date:  1999-11       Impact factor: 5.532

5.  Primate testing of TGN1412: right target, wrong cell.

Authors:  M Pallardy; T Hünig
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

6.  Gene expression profile of Th1 and Th2 cytokines and their receptors in human and nonhuman primates.

Authors:  A Ram Jeong; Shin Nakamura; Fusako Mitsunaga
Journal:  J Med Primatol       Date:  2008-05-02       Impact factor: 0.667

7.  Basophils contribute to T(H)2-IgE responses in vivo via IL-4 production and presentation of peptide-MHC class II complexes to CD4+ T cells.

Authors:  Tomohiro Yoshimoto; Koubun Yasuda; Hidehisa Tanaka; Masakiyo Nakahira; Yasutomo Imai; Yoshihiro Fujimori; Kenji Nakanishi
Journal:  Nat Immunol       Date:  2009-05-24       Impact factor: 25.606

Review 8.  The biology of IGE and the basis of allergic disease.

Authors:  Hannah J Gould; Brian J Sutton; Andrew J Beavil; Rebecca L Beavil; Natalie McCloskey; Heather A Coker; David Fear; Lyn Smurthwaite
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

9.  IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.

Authors:  Sophia N Karagiannis; Marguerite G Bracher; James Hunt; Natalie McCloskey; Rebecca L Beavil; Andrew J Beavil; David J Fear; Richard G Thompson; Nicholas East; Frances Burke; Robert J Moore; David D Dombrowicz; Frances R Balkwill; Hannah J Gould
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

10.  Interleukin 1 and tumour necrosis factor alpha may be responsible for the lytic mechanism during anti-tumour antibody-dependent cell-mediated cytotoxicity.

Authors:  A M Pullyblank; P J Guillou; J R Monson
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

View more
  8 in total

Review 1.  IgE immunotherapy against cancer.

Authors:  Lai Sum Leoh; Tracy R Daniels-Wells; Manuel L Penichet
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

Review 2.  IgE Antibodies against Cancer: Efficacy and Safety.

Authors:  Jitesh Chauhan; Alex J McCraw; Mano Nakamura; Gabriel Osborn; Heng Sheng Sow; Vivienne F Cox; Chara Stavraka; Debra H Josephs; James F Spicer; Sophia N Karagiannis; Heather J Bax
Journal:  Antibodies (Basel)       Date:  2020-10-16

Review 3.  Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments.

Authors:  Alex J McCraw; Jitesh Chauhan; Heather J Bax; Chara Stavraka; Gabriel Osborn; Melanie Grandits; Jacobo López-Abente; Debra H Josephs; James Spicer; Gerd K Wagner; Sophia N Karagiannis; Alicia Chenoweth; Silvia Crescioli
Journal:  Cancers (Basel)       Date:  2021-09-04       Impact factor: 6.575

Review 4.  AllergoOncology - the impact of allergy in oncology: EAACI position paper.

Authors:  E Jensen-Jarolim; H J Bax; R Bianchini; M Capron; C Corrigan; M Castells; D Dombrowicz; T R Daniels-Wells; J Fazekas; E Fiebiger; S Gatault; H J Gould; J Janda; D H Josephs; P Karagiannis; F Levi-Schaffer; A Meshcheryakova; D Mechtcheriakova; Y Mekori; F Mungenast; E A Nigro; M L Penichet; F Redegeld; L Saul; J Singer; J F Spicer; A G Siccardi; E Spillner; M C Turner; E Untersmayr; L Vangelista; S N Karagiannis
Journal:  Allergy       Date:  2017-01-23       Impact factor: 13.146

Review 5.  Harnessing the Anti-Tumor Mediators in Mast Cells as a New Strategy for Adoptive Cell Transfer for Cancer.

Authors:  Mohammad Fereydouni; Mona Motaghed; Elnaz Ahani; Tal Kafri; Kristen Dellinger; Dean D Metcalfe; Christopher L Kepley
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

6.  Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma.

Authors:  Panagiotis Karagiannis; Federica Villanova; Debra H Josephs; Isabel Correa; Mieke Van Hemelrijck; Carl Hobbs; Louise Saul; Isioma U Egbuniwe; Isabella Tosi; Kristina M Ilieva; Emma Kent; Eduardo Calonje; Mark Harries; Ian Fentiman; Joyce Taylor-Papadimitriou; Joy Burchell; James F Spicer; Katie E Lacy; Frank O Nestle; Sophia N Karagiannis
Journal:  Oncoimmunology       Date:  2015-06-03       Impact factor: 8.110

Review 7.  Targeting folate receptor alpha for cancer treatment.

Authors:  Anthony Cheung; Heather J Bax; Debra H Josephs; Kristina M Ilieva; Giulia Pellizzari; James Opzoomer; Jacinta Bloomfield; Matthew Fittall; Anita Grigoriadis; Mariangela Figini; Silvana Canevari; James F Spicer; Andrew N Tutt; Sophia N Karagiannis
Journal:  Oncotarget       Date:  2016-08-09

Review 8.  IgE Antibodies: From Structure to Function and Clinical Translation.

Authors:  Brian J Sutton; Anna M Davies; Heather J Bax; Sophia N Karagiannis
Journal:  Antibodies (Basel)       Date:  2019-02-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.